Pain Medicine

Biography

Mark Versavel, MD, PhD, MBA is President and Founder of vZenium LLC, providing consulting services in clinical drug development in neurology and psychiatry, and Principal of akta Pharmaceutical Development. Mark is consulting CMO at Alzheon and responsible for clinical development of ALZ-801, a prodrug of tramiprosate, in Alzheimer’s Disease. He has 25 years of clinical development experience in multiple neurology and psychiatry indications across the areas of clinical pharmacology, early and late phase clinical trials and support of marketed products. Mark has worked for Pfizer from 1999 till 2003 in France as international clinical lead for pregabalin (Lyrica) in neuropathic pain and epilepsy, and from 2003 till 2008 in New London / Groton as local clinical lead for sumanirole in Parkinson’s disease and restless legs syndrome, and global clinical lead for ziprasidone (Geodon) in schizophrenia and bipolar disorder. Mark received his MD from the University of Antwerp in 1983, PhD in clinical pharmacology from the Humboldt University in Berlin in 2003 for the validation of a computerized cognition test system, and MBA from the University of Michigan in 2003.

Research Interest